A list of commonly used measurement tools for psoriasis management and clinical trials.
CDLQI: tHE CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX: MEASURING THE IMPACT OF SKIN DISEASE ON THE LIVES OF CHILDREN
A 10-question questionnaire based on the experiences of children with skin disease. Available in both a text-only version as well as The Cartoon CDLQI, with each question illustrated by a cartoon based on the theme of the question, catering to younger children.
Link and free download available
DLQI: DERMATOLOGY QUALITY OF LIFE INDEX: Measuring disease severity and quality of life
A simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages to measure disease severity and quality of life.
To express the severity of psoriasis by measuring redness, thickness, and scaliness of the lesions, weighed by the area of involvement.
Physician's assessment of the severity of disease based on a scale from clear to very severe.
PEST: Psoriasis Epidemiology Screening Tool
PEST is a validated screening tool for psoriatic arthritis (PsA) and it is recommended that patients with psoriasis who do not have a diagnosis of PsA complete an annual PEST questionnaire (NICE psoriasis guidelines 2012). A score of 3 or more indicates referral to rheumatology should be considered.
HELP US ENHANCE OUR LIST OF AVAILABLE TREATMENT GUIDELINES. SEND INFORMATION AND LINKS TO INFO@PSORIASISCOUNCIL.ORG
congress coverage AAD 2019 Annual Meeting Read the psoriasis highlights from the congress learn more
Psoriasis News Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology6/11/2019 9:58:00 AM Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments6/5/2019 12:03:00 PMCorticosteroid therapy is regarded as first-line therapy for treating mild psoriasis and recalcitrant lesions. Members of the IPC Topical Therapies Working Group reviewed available international topical corticosteroids guidelines in order to understand current information and to identify areas that would benefit from greater practical guidance for dermatologists. FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States4/29/2019 7:28:00 AM AbbVie Announces Approval of SKYRIZI™ for the Treatment of Psoriasis in US, Canada, Europe and Japan4/28/2019 8:26:00 PM More News